NHS-Modified MMAF TFA

Cat. No.: HY-139325A: FAQs
Data Sheet Handling Instructions Technical Support

NHS-Modified MMAF (intermediat 210) TFA is an intermediate which can be used for producing the anti-mesothelin binder-agent conjugates (ADCs).

For research use only. We do not sell to patients.

NHS-Modified MMAF TFA Chemical Structure

Size	Stock	Quantity
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	Get quote
200 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other Forms of NHS-Modified MMAF TFA:

NHS-Modified MMAF Get quote

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All Drug-Linker Conjugates for ADC Isoform Specific Products:

View All Isoforms

Auristatin Camptothecins Daunorubicins/Doxorubicins Duocarmycins Maytansinoids Pyrrolobenzodiazepines Traditional Cytotoxic Agents

Biological Activity
Purity & Documentation
References
Customer Review

Description

NHS-Modified MMAF (intermediat 210) TFA is an intermediate which can be used for producing the anti-mesothelin binder-agent conjugates (ADCs)^[1].

In Vitro

ADCs are comprised of an antibody to which is attached an ADC cytotoxin through an ADC linker.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

1165.34

Formula

C₅₇H₈₇F₃N₈O₁₄

SMILES

O=C(N1CCCCO1)[C@@H](NC([C@H](C)[C@H]([C@@]2([H])N(CCC2)C(C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)CCCCCC(ON3C(CCC3=O)=O)=O)=O)=O)=O)OC)=O)CC4=CNC5=CC=CC=C45.OC(C(F)(F)F)=O

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Solvent & Solubility

In Vitro:

DMSO : 16 mg/mL (13.73 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	0.8581 mL	4.2906 mL	8.5812 mL
5 mM	0.1716 mL	0.8581 mL	1.7162 mL
10 mM	0.0858 mL	0.4291 mL	0.8581 mL

View the Complete Stock Solution Preparation Table

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

Purity & Documentation

Handling Instructions (2659 KB)

References

[1]. Lerchen HG, et, al. Novel binder-drug conjugates (adcs) and their use. WO2012143499A2.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	0.8581 mL	4.2906 mL	8.5812 mL	21.4530 mL
	5 mM	0.1716 mL	0.8581 mL	1.7162 mL	4.2906 mL
	10 mM	0.0858 mL	0.4291 mL	0.8581 mL	2.1453 mL